Showing 1531-1540 of 1616 results for "".
- New Acuvue Campaign Encourages Gen Z to Take a Social Media Breakhttps://modernod.com/news/new-acuvue-campaign-encourages-gen-z-to-take-a-social-media-break/2481606/The Acuvue brand announced the "Where Vision Meets Sight" social media campaign (#MyVisionMySight) that aims to encourage Gen Z to take social media breaks—to not only give their eyes a rest, but also recognize the impact screen time is having in their lives, according t
- Alcon Expands Plastic Bank Partnership in 2023 to Further Support Sustainability Effortshttps://modernod.com/news/alcon-expands-plastic-bank-partnership-in-2023-to-further-support-sustainability-efforts/2481591/Alcon announced the expansion of the partnership with Plastic Bank—an organization that builds recycling ecosystems in under-developed communities to fight plastic pollution while providing collection members with a path out of poverty. For each ton of plastic introduced in the marketp
- Lumibird Launches Tango Neo and UltraQ Reflex Neo Lasershttps://modernod.com/news/lumibird-launches-tango-neo-and-ultraq-reflex-neo-lasers/2481570/Following the launch of its flagship product, the Tango Reflex Neo, in December 2022, Lumibird Medical announced the launch of two additional variants within its premium Nd:YAG/SLT laser range—the UltraQ Reflex Neo and Tango Neo. A fully integrated Q-switched Nd:YAG lase
- Survey: Employees Value Vision Care as Much as Dental, but Many are Leaving Benefits on the Tablehttps://modernod.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/A new survey conducted by The Harris Poll for XP Health finds that employees value vision care as much as dental, but many are confused about how to take advantage of it—even when they have vision benefits. According to the
- Cedars-Sinai Analysis Evaluates How Retinal Changes Correspond to Cognitive Changes in Alzheimer’s Diseasehttps://modernod.com/news/new-insights-eye-damage-in-alzheimers-disease-patients/2481455/Cedars-Sinai investigators have produced an analysis evaluating how retinal changes correspond to brain and cognitive changes in Alzheimer’s disease patients. Investigators looked at retinal and brain tissue samples collected over 14 years from 86 human donors—the
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Market Scope: Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12 Billionhttps://modernod.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/Market Scope forecasts that the global refractive surgery industry will generate $12 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent. The health care research company expects revenue at the manufacturer level to
- Verana Health Study of Patients with Dry AMD Published in International Ophthalmologyhttps://modernod.com/news/verana-health-study-of-patients-with-dry-amd-published-in-international-ophthalmology/2481301/Verana Health—a digital health company elevating quality in real-world data—announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosishttps://modernod.com/news/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leber-congenital-amaurosis/2481300/Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). “Receiving orphan drug designation is
- NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketinghttps://modernod.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month. CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—t